|
Market Closed -
Nasdaq
00:00:00 05/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 151.00 USD | -0.15% |
|
+3.65% | +23.02% |
| 09-03 | AbbVie's blood cancer therapy lowers disease progression, death risk in trial | RE |
| 09-01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 157.41 | +4.25% | 27 | ||||||
| 1,315.56 | +14.46% | 29 | ||||||
| 275.64 | +0.15% | 22 | ||||||
| 276.59 | +7.85% | 29 | ||||||
| 370.31 | +3.73% | 18 | ||||||
| 155.01 | -3.15% | 21 | ||||||
| 213 | +31.21% | 22 | ||||||
| 389.69 | -10.87% | 29 | ||||||
| 309.73 | +3.62% | 23 | ||||||
| 28.61 | +0.55% | 26 | ||||||
| 569.54 | +4.29% | 26 | ||||||
| 66.21 | -0.92% | 24 | ||||||
| 94.28 | +23.63% | 23 | ||||||
| 21.69 | +17.45% | 20 | ||||||
| 9,323.33 | +37.21% | 15 | ||||||
| 6,603.31 | +14.78% | 16 | ||||||
| 57.39 | +17.48% | 18 | ||||||
| 71.35 | +55.05% | 17 | ||||||
| 41.6 | +14.41% | 10 | ||||||
| 4.211 | +19.36% | 17 | ||||||
| Average | 1,017.22 | +12.73% | 22 | ||||||
| Weighted average by Cap. | 699.11 | +8.38% | 24 |
- Stock Market
- Stocks
- GILD Stock
- Sector Gilead Sciences, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
